Comparison Of iStent to Laser in Exfoliation Glaucoma Helsinki Study Group

Who May Qualify: - Signed consent of information - Clinical significant cataract - Able to attend 12 month period - Mild to moderate exfoliation glaucoma according to European glaucoma society guidelines (EGS) - Group I stable glaucoma (IOP within individual target IOP), and group II unstable glaucoma (IOP above individual target IOP) with baseline glaucoma medication - Target IOP ≥16 - Able to understand Finnish, Swedish or English Who Should NOT Join This Trial: - Clinical set target IOP \< 16 mmHg in advanced glaucoma - Baseline IOP prior to enrolment ≥30 mmHg, and ≥3 glaucoma medications - Closed angle - Congenital angle anomaly - Clinically significant corneal dystrophy or other hindering corneal condition - Unable to use topical medical therapy - Central corneal thickness of less than 480um or more than 620um - Active uveitis, cystic macular edema (CME), exudative age-related macular degeneration, proliferative diabetic retinopathy or clinical significant macular edema, intraocular neoplasm, intraocular injections, intraocular lens luxation, phacodonesis. - Previous intraocular surgery, refractive surgery or cycloablation - Two or more prior SLT or laser trabeculoplasty - Unable to participate due to another medical disease or condition - Participating in another clinical trial Always talk to your doctor about whether this trial is right for you.